Opinions Paul MacDonald
Celgene CorpCELGPAST TOP PICKMar 21, 2018
Paul MacDonaldStock price when the opinion was issued
As of Nov 20, 2019. Market Open.
You might be interested:
(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.
Bruce MurrayBruce Murray
Paul MacDonald
(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.
They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.
(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.